Movement Alert｜Guardant Health Inc. Intraday Decline 5.16%, Patent Litigation Loss and Royalty Burden Continue to Pressure Stock

Market Focus10-13 01:15

On October 13, Guardant Health Inc. fell 5.16% in regular trading to $158.81 per share, with turnover of $107 million. The decline reflects ongoing market digestion of a significant patent infringement ruling.

The company previously lost a lawsuit filed by TwinStrand Biosciences and the University of Washington, with the court affirming a willful infringement verdict and awarding over $245.2 million in damages, accrued royalties, and interest through May 31, 2026. Guardant Health must also pay a 6% royalty on sales of 11 products and services from June 1, 2026 until the patents expire on March 15, 2033, and provide quarterly accounting of U.S. sales.

The financial burden of the judgment, combined with ongoing royalty and compliance obligations, continues to weigh on investor sentiment despite prior analyst upgrades. The ruling underscores the material legal and financial overhang facing the precision oncology company.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment